Damora Therapeutics, Inc.
NASDAQ: GLTO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Jennifer A. Jarrett
- Employees
- 7
- Headquarters
- Boston, United States
- IPO year
- 2020
- Market cap
- $34.5M
- Website
- https://galecto.com
Loading GLTO…
Loading profile data…Frequently asked questions about GLTO
What does Damora Therapeutics, Inc. (GLTO) do?
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, bot...
Where does GLTO trade?
Damora Therapeutics, Inc. (GLTO) trades on the NASDAQ.
What sector is GLTO in?
Damora Therapeutics, Inc. (GLTO) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Damora Therapeutics, Inc.?
Jennifer A. Jarrett is the chief executive officer of Damora Therapeutics, Inc. (GLTO).
Where is Damora Therapeutics, Inc. headquartered?
Damora Therapeutics, Inc. is headquartered in United States.
Does GLTO pay a dividend?
Damora Therapeutics, Inc. (GLTO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GLTO go public?
Damora Therapeutics, Inc. (GLTO) completed its initial public offering in 2020.